Stifel downgraded Reata Pharmaceuticals (RETA) to Hold from Buy with a price target of $172.50, up from $110. Biogen (BIIB) agreed to acquire Reata for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3B. Skyclarys fits “easily into (Biogen’s) rare disease footprint,” says the firm, which adds that it thinks “this was an excellent price for” Reata.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RETA:
- Biogen Snaps Up Reata Pharma In $7.3B Deal
- Biogen to acquire Reata Pharmaceuticals for $172.50 per share in cash
- Biotech Alert: Searches spiking for these stocks today
- 3 Best Stocks to Buy Now, 7/25/2023, According to Top Analysts
- Reata Pharmaceuticals price target raised to $145 from $110 at Cantor Fitzgerald